Find disease awareness content and relevant supporting materials

Consideration should be given to official guidance on the appropriate use of antibacterial agents. Klaricid Adult Sachets 250mg are indicated in adults and children 12 years and older. Clarithromycin is indicated in the treatment of infections caused by one or more susceptible organisms. Indications include: Lower respiratory tract infections for example, acute and chronic bronchitis, and pneumonia (see section 4.4 and 5.1 regarding Sensitivity Testing). Upper respiratory tract infections for example, sinusitus and pharyngitis. Clarithromycin is appropriate for initial therapy in community acquired respiratory infections and has been shown to be active in vitro against common and atypical respiratory pathogens as listed in the microbiology section. Clarithromycin is also indicated in skin and soft tissue infections of mild to moderate severity (e.g. folliculitis, cellulitis, erysipelas) (see section 4.4 and 5.1 regarding Sensitivity Testing). Clarithromycin in the presence of acid suppression effected by lansoprazole or omeprazole is also indicated for the eradication of H. pylori in patients with duodenal ulcers. See Dosage and Administration section. Clarithromycin is usually active against the following organisms in vitro: Gram-positive Bacteria: Staphylococcus aureus (methicillin susceptible); Streptococcus pyogenes (Group A beta-haemolytic streptococci); alpha-haemolytic streptococci (viridans group); Streptococcus (Diplococcus) pneumoniae ; Streptococcus agalactiae; Listeria monocytogenes . Gram-negative Bacteria: Haemophilus influenzae; Haemophilus parainfluenzae; Moraxella (Branhamella) catarrhalis; Neisseria gonorrhoeae; Legionella pneumophila; Bordetella pertussis; Helicobacter pylori; Campylobacter jejuni. Mycoplasma: Mycoplasma pneumoniae; Ureaplasma urealyticum. Other Organisms: Chlamydia trachomatis; Mycobacterium avium; Mycobacterium leprae. Anaerobes: Macrolide-susceptible Bacteroides fragilis; Clostridium perfringens; Peptococcus species; Peptostreptococcus species; Propionibacterium acnes . Clarithromycin has bactericidal activity against several bacterial strains. These organisms include Haemophilus influenzae; Streptococcus pneumoniae; Streptococcus pyogenes; Streptococcus agalactiae; Moraxella (Branhamella) catarrhalis; Neisseria gonorrhoeae; Helicobacter pylori and Campylobacter spp. The activity of clarithromycin against H. pylori is greater at neutral pH than at acid pH.

Consideration should be given to official guidance on the appropriate use of antibacterial agents. Klaricid XL 500 mg Tablets are indicated in adults and children 12 years and older. Klaricid XL 500 mg Tablets are indicated for treatment of infections caused by susceptible organisms. Indications include: Lower respiratory tract infections for example, acute and chronic bronchitis, and pneumonia (see section 4.4 and 5.1 regarding Sensitivity Testing). Upper respiratory tract infections for example, sinusitis and pharyngitis. Klaricid XL 500 mg Tablets are also indicated in skin and soft tissue infections of mild to moderate severity, for example folliculitis, cellulitis and erysipelas (see section 4.4 and 5.1 regarding Sensitivity Testing).

Klaricid IV 500 mg is indicated in adults and children 12 years and older. Klaricid IV 500 mg is indicated whenever parenteral therapy is required for treatment of infections caused by susceptible organisms in the following conditions; - Lower respiratory tract infections for example, acute and chronic bronchitis, and pneumonia (see section 4.4 and 5.1 regarding Sensitivity Testing). - Upper respiratory tract infections for example, sinusitis and pharyngitis. - Skin and soft tissue infections (e.g. folliculitis, cellulitis, erysipelas) (see section 4.4 and 5.1 regarding Sensitivity Testing). Consideration should be given to official guidance on the appropriate use of antibacterial agents.

For treatment of fluid and electrolyte loss associated with acute diarrhoea .

For the treatment of chronic constipation in children 1 to 11 years of age. For the treatment of faecal impaction in children from the age of 5 years, defined as refractory constipation with faecal loading of the rectum and/or colon.

For treatment of fluid and electrolyte loss associated with acute diarrhoea .

For the treatment of chronic constipation in adults and children above the age of 12. Movicol Chocolate is also effective in resolving faecal impaction, defined as refractory constipation with faecal loading of the rectum and/or colon.

Oral correction of fluid and electrolyte loss in infants, children and adults. Treatment of watery diarrhoea of various aetiologies including gastro-enteritis, in all age groups.

Mild to moderate ulcerative colitis

Kaftrio granules are indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (CF) in paediatric patients aged 2 to less than 6 years who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene (see section 5.1).